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Abstract
Monocytes are involved in adverse left ventricular (LV) remodelling following myocardial infarction (MI). To provide 
therapeutic opportunities we aimed to identify gene transcripts in monocytes that relate to post-MI healing and evaluated 
intervention with the observed gene activity in a rat MI model. In 51 MI patients treated by primary percutaneous coronary 
intervention (PCI), the change in LV end-diastolic volume index (EDVi) from baseline to 4-month follow-up was assessed 
using cardiovascular magnetic resonance imaging (CMR). Circulating monocytes were collected at day 5 (Arterioscler 
Thromb Vasc Biol 35:1066–1070, 2015; Cell Stem Cell 16:477–487, 2015; Curr Med Chem 13:1877–1893, 2006) after 
primary PCI for transcriptome analysis. Transcriptional profiling and pathway analysis revealed that patients with a decreased 
LV EDVi showed an induction of type I interferon (IFN) signalling (type I IFN pathway: P value < 0.001; false discovery 
rate < 0.001). We subsequently administered 15,000 Units of IFN-α subcutaneously in a rat MI model for three consecutive 
days following MI. Cardiac function was measured using echocardiography and infarct size/cardiac inflammation using 
(immuno)-histochemical analysis. We found that IFN-α application deteriorated ventricular dilatation and increased infarct 
size at day 28 post-MI. Moreover, IFN-α changed the peripheral monocyte subset distribution towards the pro-inflammatory 
monocyte subset whereas in the myocardium, the presence of the alternative macrophage subset was increased at day 3 
post-MI. Our findings suggest that induction of type I IFN signalling in human monocytes coincides with adverse LV remod-
elling. In rats, however, IFN-α administration deteriorated post-MI healing. These findings underscore important but also 
contradictory roles for the type I IFN response during cardiac healing following MI.
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Introduction
Adverse left ventricular (LV) remodelling is an important 
cause of heart failure and cardiac death after myocardial 
infarction (MI) [14]. Upon MI, an inflammatory response 
is initiated which involves recruitment of monocytes and 
macrophages into the infarcted site to promote removal of 
tissue debris and subsequently to stimulate tissue repair 
[22]. Monocytes consist of a heterogeneous pool of cells 
that are distinguished into specific subsets and can adapt 
their function in response to tissue injury [8, 22]. Although 
recruitment of monocytes is a prerequisite for proper infarct 
healing, excessive accumulation of activated monocyte and 
macrophage subsets into the myocardium may deleteri-
ously affect post-infarct healing [22, 31]. Clinical studies 
have reported an association between the development of 
adverse LV remodelling and post-MI monocytosis [15, 18], 
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indicating the importance of monocyte involvement in the 
pathogenesis of adverse LV remodelling. Hence, increased 
understanding of the monocyte response in MI patients 
is needed to provide new clues for treatments that could 
improve the LV remodelling process.
To beneficially influence the monocyte response follow-
ing MI, several clinical studies have focused on unravelling 
specific monocyte surface markers to quantify and influ-
ence subset recruitment into the injured myocardium [5, 10, 
19]. In an earlier study, we reported in MI patients that high 
levels of the peripheral pro-inflammatory monocyte subset 
were negatively associated with regional systolic function 
at 4-month follow-up [32]. However, functional gene tran-
scripts of monocytes in MI patients that relate to adverse 
LV remodelling following MI have been poorly described, 
while this could provide essential therapeutic targets that 
influence monocyte functioning [16]. In the current study, 
we addressed this issue by investigating the transcriptome 
of circulating monocytes of the same MI patient group as 
our previous study [32] to subsequently correlate this with 
changes in cardiac function at 4-month follow-up. This 
revealed that enhanced signalling of the type I interferon 
(IFN) in monocytes of MI patients beneficially affects post-
MI cardiac healing. These results implicate that systemic 
elevation of type I IFN may positively affect post-MI adverse 
LV remodelling. To evaluate this, we used a rat MI model 
and administrated the type I IFN, IFN-α, for three consecu-
tive days following MI and analysed the effect of IFN-α on 
myocardial infarct size, cardiac function and the inflamma-
tory response.
Methods
Detailed methods are described in the supplementary 
material.
Patient study and procedures
The present study is an ancillary study of the HEBE study, 
of which the study design, procedures and main results have 
been reported previously [9]. Briefly, the HEBE study was 
a multicentre, randomized trial, investigating the effect of 
intracoronary infusion of autologous bone marrow mononu-
clear cells and peripheral blood mononuclear cells (PBMC) 
after ST-segment elevation myocardial infarction. For this 
ancillary study, patients of the PBMC group were selected 
from which both the CMR and PBMC data were completely 
available (n =51). All patients underwent baseline CMR at 
3 days [3, 4] after primary PCI, with a minimum of 2 days 
between PCI and CMR. With CMR, calculated functional 
parameters were indexed for body surface area as reported 
previously [9]. At 4-month follow-up, CMR was repeated 
and the change in LV end-diastolic volume index (EDVi) 
from baseline to 4-month follow-up was used as a measure 
of the extent of LV remodelling. Whole blood was collected 
at 5 days [4–6] after primary PCI. The study was conducted 
in accordance with the Declaration of Helsinki, and the 
study protocol was approved by Institutional Review Boards 
of the participating institutes. All patients gave informed 
consent. The trial was registered at the Netherlands Trial 
Register (#NTR166; www.trial regis ter.nl) and at the Inter-
national Standard Randomized Controlled Trial register 
(#ISRCTN95796863; http://isrct n.org).
Animals and experimental MI procedure
Male Wistar rats (n = 48, age 6–8 weeks, Harlan Labora-
tories, Horst, the Netherlands) weighing between 350 and 
420 g were used. The study was approved by the VU Uni-
versity Amsterdam animal ethics and welfare committee. 
The VU University Amsterdam is licensed according to the 
2010/63/EU guidelines. The rats involved in the current 
study were accommodated and cared for according to the 
guidelines described in appendix A of EST No. 123. Induc-
tion of MI and the use of medetomidine–sufentanil as anaes-
thesia are performed as described previously [29]. Briefly, 
the left anterior descending artery (LAD) was ligated for 
40 min, followed by reperfusion and closure of the thorax. 
Post-MI analgesia was continued as suggested earlier [29]. 
Sham animals underwent the exact same procedures except 
for ligation of the LAD.
Experimental setup
Following MI or sham, rats received 15,000 Units of mam-
malian rat Interferon Alpha (PBL Assay science) subcuta-
neously, diluted in 1 mL saline within 30 min following the 
surgical procedure for three consecutive days. The doses of 
subcutaneous 15,000 Units/mL was based upon pharmacoki-
netic properties of type I IFN [17], and usage of type I IFN 
in (pre)clinical settings during inflammatory diseases [21, 
28, 34]. A subgroup was killed at 3 days following MI or 
sham (day 3) (MI: n = 10, sham: n = 3) and the remainder 
at 28 days following MI or sham (day 28) (MI: n = 8, sham: 
n = 3). Placebo MI and sham rats were treated equally but 
received a placebo subcutaneous injection containing 1 mL 
saline (day 3 MI n = 8, sham n = 4; day 28 MI n = 8, sham 
n = 4).
Statistical analysis
Data with normal distribution are expressed as mean ± SD 
and data with non-normal distribution are given as median 
value (25th–75th percentile). Categorical data are presented 
as number (%). To test for differences between groups with 
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a normal distribution, the Student’s t test was used and for 
data with a non-normal distribution, the Mann–Whitney U 
test was used for unpaired data and the Wilcoxon signed rank 
test for paired data. The Fisher’s exact test or the Chi-square 
test was used for testing associations between categorical 
data. A two-sided P value < 0.05 was considered statistically 
significant. Statistical analysis was performed with Statisti-
cal Package for Social Sciences software (SPSS 22.0 for 
Windows, SPSS Inc.).
Results
Patient characteristics
The baseline characteristics of the patient study population 
are shown in Supplementary Table S2. The mean age of the 
study population was 56 ± 9 years, 82% was male, and the 
median time from onset of symptoms to reperfusion therapy 
was 3.0 (2.2–4.8) h. Mean baseline infarct size was 18 ± 9% 
of the LV. A marked variety was observed in the change 
of LV EDVi from baseline to 4-month follow-up amongst 
patients. The LV EDVi increased from 98 ± 16 mL/m2 at 
baseline to 104 ± 22 mL/m2 at follow-up (P = 0.01), with a 
change in LV EDVi of 6 ± 15% (Fig. 1a). At 4-month fol-
low-up, 37 patients (73%) showed an increase in LV EDVi. 
Supplementary Table S2 shows the baseline characteristics 
of the study population after stratification by change in LV 
EDVi. Mean LV ejection fraction (EF) was 42 ± 10% at 
baseline and was increased to 46 ± 9% at 4-month follow-
up (P <0.05), with a change in LV EF of 4 ± 7% (Fig. 1b).
Patients without adverse LV remodelling show 
induced type I IFN signalling
To identify gene transcripts that are significantly related 
to adverse LV remodelling following MI, we compared 
the transcriptome of monocytes between patients with 
a decreased LV EDVi and patients with an increased LV 
EDVi at 4-month follow-up. Whole genome transcriptome 
analysis revealed a total of 47 probes (45 unique genes) that 
were significantly differentially expressed (Supplementary 
Table S3). All significant genes were expressed at higher 
levels in patients with a decreased LV EDVi. Amongst these 
were several IFN-stimulated genes (ISGs). Verification of 
gene array expression data by real-time RT-PCR was per-
formed for a selection of ISGs and agreed with the gene 
array data (Supplementary Table S4). Next, we performed 
transcriptome analysis at the pathway level. The top ten 
significant pathways were all expressed at higher levels in 
patients with a decreased LV EDVi, and were all related 
to IFN signalling (Table 1). The most significant path-
way was the MOSERLE_IFNA_RESPONSE pathway (P 
value < 0.001; false discovery rate < 0.001), containing 50 
genes that are upregulated in ovarian cancer progenitor cells 
in response to the type I IFN, IFN-α [20]. Figure 1c shows 
the expression of this type I IFN signalling pathway in rela-
tion to the change in LV EDVi, visualized in a heatmap. 
Furthermore, analysis of transcription factor-binding sites 
of genes that were expressed at significantly higher levels in 
patients with a decreased LV EDVi revealed transcription 
factor-binding motifs involved in IFN signalling, corroborat-
ing the above findings (Supplementary Table S5).
Administration of IFN‑α following experimental MI 
results in LV dilatation
Since elevated type I IFN signalling in monocytes of MI 
patients coincided with reduced adverse LV remodelling, 
we hypothesized that systemic elevation through type I IFN 
protein could exert a comparable effect. To assess this, we 
used a rat MI model and systemically administered IFN-α 
following MI for three consecutive days. Rats that received 
a placebo injection served as control. The effect of MI on 
the endogenous expression of ISGs in rat PBMC and the 
effect of IFN-α administration hereon were primarily evalu-
ated. This showed that MI caused increased Cxcl10 mRNA 
expression levels from day 2 to day 3 and IFN-α admin-
istration increased its expression at day 2 (Supplementary 
Figure S1). This suggests that exogenous IFN-α administra-
tion could induce an early expression of ISGs in circulating 
PBMC following MI.
To determine the effect of IFN-α application on post-MI 
adverse LV remodelling, echocardiography was performed 
(Fig. 2a, e and g). This showed that MI caused ventricular 
dilatation, shown by a significant increase of the systolic 
left ventricle internal diameter (LVIDs) (Fig. 2c; P < 0.05) 
and area (Fig. 2h; P < 0.05) in comparison to sham at day 
28. Post-MI IFN-α administration deteriorated ventricular 
dilatation at day 28, shown by a further increase of LVID 
in diastole (Fig. 2b; P < 0.05) and of the LV area at day 
28 in both diastole (Fig. 2f; P < 0.01) and systole (Fig. 2h; 
P < 0.05). Also, we showed that MI decreased fractional 
shortening (FS), reflecting a reduction in cardiac function-
ing. Post-MI IFN-α also decreased FS, although not signifi-
cantly different in comparison to placebo (Fig. 2d; P = 0.06). 
In sham rats, IFN-α administration did not affect the meas-
ured cardiac parameters (Fig. 2b–d, f and h).
IFN‑α administration increases infarct necrosis 
and infarct size
To determine the effect of IFN-α on post-MI cardiac 
healing, we evaluated the infarct size and the percent-
age of necrotic and granulation tissue at day 3 and the 
percentage of granulation and fibrotic tissue at day 28 
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via histochemical analysis (Fig. 3). In sham animals, no 
damaged myocardial tissue was found, nor after IFN-α 
administration (Fig. 3b). In MI rats, IFN-α administration 
resulted in more necrotic tissue and less granulation tis-
sue at day 3 as compared to placebo (Fig. 3c, d; P = 0.05) 
whereas at day 28, no difference in infarct tissue com-
position was detected (Fig. 3f). However, post-MI IFN-α 
administration resulted in a significantly larger infarct area 
at day 28 in comparison to placebo (Fig. 3e; P < 0.01).
Fig. 1  Increased IFN type I 
expression in monocytes of 
MI patients with a decreased 
EDVi baseline–4-month FU. a 
The change in LV EDVi from 
baseline to 4-month follow-up. 
b The change in LV EF from 
baseline to 4-month follow-
up. c Heat map showing the 
expression of genes of the 
MOSERLE_IFNA_RESPONSE 
pathway supervised by the 
change in LV EDVi from base-
line to 4-month follow-up. Each 
column represents one patient. 
Patients with a decreased LV 
EDVi at 4-month follow-up are 
placed on the left side (n = 14) 
and patients with an increased 
LV EDVi on the right side 
(n = 37). Red denotes relatively 
high gene expression, green rep-
resents relatively low-expressed 
genes. Note the relative high 
expression of genes of the 
MOSERLE_IFNA_RESPONSE 
pathway in patients with a 
decreased LV EDVi at 4-month 
post-MI (right side). Statisti-
cal analyses are performed 
using the Student’s t test. EDVi 
end-diastolic volume index, EF 
ejection fraction, FU follow-up, 
LV left ventricular
Basic Research in Cardiology           (2019) 114:1  
1 3
Page 5 of 12     1 
Systemic IFN‑α administration following MI affects 
monocyte and macrophage subset distribution
As an exaggerated monocyte response has been shown to 
highly correlate with increased infarct size and deterio-
rated cardiac function [31, 32] and IFN-α has been shown 
to modulate immune responses [7], we analysed the effect 
of IFN-α administration on circulating monocyte sub-
set distribution and the level of macrophages within the 
infarcted area. Using flow cytometry analysis, circulat-
ing rat monocytes were subdivided into pro-inflammatory 
classical subsets (CD43-lo) and reparative non-classical 
subsets (CD43-hi; Fig. 4a). This showed that following 
MI, the percentage of CD43-lo monocytes is significantly 
reduced at day 3 in comparison to baseline (P < 0.05) 
(Fig.  4b). Post-MI IFN-α administration significantly 
increased CD43-lo monocytes already at day 2 in com-
parison to baseline (P = 0.000) (Fig. 4b, red bars) and also 
induced a significant increase of the CD43-lo monocytes at 
both day 2 (P < 0.05) and day 3 (P < 0.05) in comparison 
to placebo (Fig. 4b).
Using quantitative immunohistochemical analysis 
(Fig. 5a–c), we showed that IFN-α administration did not 
affect the total  CD68+ macrophages infiltrate at day 3 
(Fig. 5e) or at day 28 (Fig. 5g). However, at day 3, post-MI 
IFN-α administration significantly elevated the alternative 
macrophages, without affecting the pro-inflammatory mac-
rophage abundance (Fig. 5f; P < 0.05). Moreover, at day 28, 
MI showed an equal distribution of pro-inflammatory clas-
sical and reparative alternative macrophages in the infarct. 
IFN-α administration, however, resulted in a distribution 
towards more classical macrophages than alternative mac-
rophages in the infarcted myocardium (Fig. 5h; P < 0.05), 
albeit this was not significantly different in comparison to 
placebo.
Discussion
In the current study, we show contradictory roles of type I 
IFN and its signalling pathway in post-MI cardiac healing. 
In patients, transcriptome analysis in circulating monocytes 
of MI patients revealed that an induced expression of ISGs 
was associated with a decreased and, therefore, more pre-
served LV EDVi at 4-month follow-up. This profile repre-
sented the type I IFN signalling pathway suggesting that 
type I IFNs, and hence induction of type I IFN signalling 
in monocytes, positively correlate with beneficial post-MI 
LV remodelling in patients. However, in an experimental 
rat MI model, we showed that administration of exogenous 
IFN-α protein following MI resulted in more necrotic and 
less granulation tissue at day 3 and also exaggerated left 
ventricular dilatation together with an increased infarct size 
at day 28 in comparison to placebo-treated MI. Moreover, 
IFN-α administration increased the monocyte subset distri-
bution following MI towards the more inflammatory CD43-
lo subset at day 2 and day 3 whereas in the myocardium, 
the alternative macrophage subset was more present at day 
3 after IFN-α administration. These results indicate that in 
a rat MI model, IFN-α application deteriorated the cardiac 
healing process following MI.
In patients, there is a marked difference in outcome fol-
lowing MI. Adverse LV remodelling occurs in approxi-
mately 15–50% of MI patients and is associated with heart 
failure and cardiac death [14, 35]. Monocytes have been 
implicated in the pathophysiology of adverse LV remodel-
ling post-MI [4, 5] and with the current study, we are the first 
to investigate the gene transcripts of circulating monocytes 
in relation to the LV remodelling process following MI.
Sufficient healing of the infarcted area has been linked by 
several studies to a well-balanced inflammatory response. 
[6, 12, 22, 33] Type I IFN activation can either induce 
Table 1  Pathway analysis
The change in LV EDVi was used as a quantitative parameter to identify significantly associated path-
ways. The top ten significant pathways are listed (sorted by score). Patients with an increased LV EDVi at 
4-month follow-up showed attenuated type I IFN signalling
FDR false discovery rate
Gene set name Score P value FDR
MOSERLE_IFNA_RESPONSE − 3.33 0.000 0.000
UROSEVIC_RESPONSE_TO_IMIQUIMOD − 2.83 0.000 0.000
ZHANG_INTERFERON_RESPONSE − 2.74 0.000 0.000
EINAV_INTERFERON_SIGNATURE_IN_CANCER − 2.65 0.000 0.000
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS − 2.5 0.000 0.000
DAUER_STAT3_TARGETS_DN − 2.37 0.000 0.000
BROWNE_INTERFERON_RESPONSIVE_GENES − 2.28 0.000 0.000
RADAEVA_RESPONSE_TO_IFNA1_UP − 1.87 0.000 0.000
ZHU_CMV_8_HR_UP − 1.74 0.000 0.000
SANA_RESPONSE_TO_IFNG_UP − 1.72 0.000 0.000
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Fig. 2  IFN-α administration results in ventricular dilatation in rats. 
2D echocardiography measurements at day 28 showing a images 
of the M-mode parameters LVIDd and LVIDs which are quantified 
and presented in b and c showing mean ± SD. d Relative change in 
LVIDd and LVIDs presented as FS(%). Short axis of the LV area at 
day 28 in diastole in e (image) and f (quantification) as well as in 
systole in g (image) and h (quantification). MI myocardial infarction, 
IFN-α interferon alpha, LVIDd left ventricle internal diameter in dias-
tole and LVIDs left ventricle internal diameter in systole. Statistical 
analysis are performed using the Student’s t test
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inflammation following a viral or bacterial infection, or 
contain a suppressive role in certain chronic infections [1, 
11]. Variability in this response is highly dependent on cell 
type, pathogens and the environmental context [1]. In rats, 
we showed that post-MI IFN-α administration altered the 
distribution of circulating monocyte subsets towards the pro-
inflammatory CD43-lo monocyte at day 2 in comparison to 
placebo, a shift which has generally been associated with 
Fig. 3  IFN-α administration increases the necrotic tissue area at day 
3 and the total infarct size at day 28. a Images of a rat myocardial 
PTAH stain at day 3 with the infarcted area indicated by a yellow 
line. Scale bar represents 2  mm. b Quantification of the infarcted 
areas at day 3. c Magnification of the PTAH stain showing the 
infarcted area with necrotic (n) and granulation tissue (g) indicated by 
yellow lines and the viable myocardium (v) indicated by white lines. 
Scale bar represents 200 µm. d Quantification of necrotic and granu-
lation tissue in the infarcted area at day 3. P values were calculated 
using the Mann–Whitney U test. e Quantification of the infarcted area 
at day 28 and f its quantification of granulation and fibrotic tissue. 
PTAH phosphotungstic acid–hematoxylin, MI myocardial infarction, 
IFN-α interferon alpha. Statistical analyses are performed using the 
Student’s t test (b and e) or the Mann–Whitney U test (d and f)
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an expanded infarcted area [31, 32]. Interestingly, in the 
infarcted area of the myocardium, post-MI IFN-α adminis-
tration increased the presence of the reparative alternative 
macrophage subset at day 3. Even though pro-inflammatory 
macrophages were still predominantly present in the infarct 
area at that time point, this could implicate that IFN-α initi-
ates an early propagation towards suppressing inflammation 
in the infarct in comparison to placebo MI rats [24, 30]. 
Remarkably, this also reveals that circulatory inflammatory 
cells do not always directly reflect the inflammatory status of 
the injured tissue. It has been suggested that type I IFN can 
affect the recruitment of monocytes and other inflammatory 
cells into the infarcted area, which could account for this 
observed difference between circulating and tissue-resident 
monocytes [3, 13, 34]. However, we did not find an effect 
of IFN-α on the number of macrophages in the myocardium 
early after MI, suggesting that IFN-α could have affected the 
inflammatory response through other mechanisms. Addition-
ally, we showed that post-MI IFN-α administration increased 
the infarcted area at day 28 and deteriorated ventricular dila-
tation, an important predictor of heart failure and ventricular 
arrhythmia development [27]. Moreover, IFN-α administra-
tion resulted in an increase of necrotic tissue and a decrease 
in granulation tissue at day 3 in comparison to placebo MI. 
This could implicate that administration of IFN-α delayed 
the infarct healing, ensuing from a lack of cell debris clear-
ance and replacement with granulation tissue.
Recently, King et al. published a study in which they 
demonstrate a negative effect of type I IFN signalling 
during healing following permanent MI in mice [13]. 
Type I IFN activation occurs classically through the 
IFN-α receptor (IFNAR). This induces activation of the 
Jak–Stat pathway resulting in Stat1 and Stat2 dimeriza-
tion that initiates nuclear translocation of IFN regulatory 
transcription factors (IRF) and subsequent transcription 
of ISGs [1, 7, 23]. King et al. demonstrated that MI acti-
vates IRF3-dependent signalling through macrophages 
upon dsDNA sensing at day 4 following MI. Induction of 
MI in irf3−/− mice showed reduced ventricular dilatation 
together with a marked decrease in infiltrated pro-inflam-
matory monocytes in comparison to MI in wild-type (wt) 
mice [13]. Moreover, King et al. showed that treatment 
with an IFNΑR-neutralizing antibody at 12 and 48 h after 
coronary artery ligation in wt mice improved cardiac func-
tioning and survival in comparison to untreated wt mice 
following MI [13]. They concluded that systemic absence 
of endogenous type I IFN signalling, even when initiated 
after coronary ligation, beneficially affects cardiac healing 
Fig. 4  IFN-α changes the 
distribution of circulating 
monocyte subsets at day 2 
following experimental MI. a 
Representative flow cytometry 
plots of mononuclear cells at 
baseline, days 2, 3 and 28. After 
baseline, rats were subdivided 
into groups (MI or MI + IFN-
α). b Quantification of the 
pro-inflammatory CD43-lo 
monocytes in MI and in IFN-
α-treated MI rats (red bars) at 
the different time points. MI 
myocardial infarction, IFN-α 
interferon alpha. Statistical 
analyses are performed using 
the Student’s t test (paired and 
unpaired)
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Fig. 5  IFN-α does not alter total macrophage infiltration in the myo-
cardium but increases alternative macrophage infiltration into the 
myocardium at day 3. Immunohistochemical images of the infarcted 
myocardium at day 3 (a–b) and day 28 (c–d) of CD68 (a and c) stain-
ing of all macrophages and CD163 (b and d) representing the repara-
tive alternative macrophages. Scale bar represents 50 µm. Quantifica-
tion of CD68 at day 3 (e) and day 28 (g) and the quantification of the 
macrophage subsets at day 3 (f) and day 28 (h). MI myocardial infarc-
tion, IFN-α interferon alpha. Data are presented as box plots show-
ing the median and 25th–75th percentile together with the minimum 
and the maximum values. Statistical analyses are performed using the 
Mann–Whitney U test (unpaired) or the Wilcoxon signed rank test 
(paired)
 Basic Research in Cardiology           (2019) 114:1 
1 3
   1  Page 10 of 12
following permanent MI. This supports our current results 
in rats showing that exogenous IFN-α administration fol-
lowing MI deteriorated cardiac healing.
Exaggerated IFN responses are increasingly associated 
with human autoimmune diseases and could detrimentally 
affect the functioning of type I IFN [1]. Also, the con-
centration and duration of IFN production together with 
specific timing of action can be crucial for accurate IFN 
functioning [1, 2]. In this regard, the findings that systemic 
IFN-α administration in rats and absence of type I IFN sig-
nalling in mice exerted a contradictory response in com-
parison to MI patients could implicate that elevated type 
I IFN signalling in monocytes does not reflect systemic 
elevated type I IFN signalling. Also, we can currently 
not exclude the response and contribution of non-mye-
loid cells after systemic IFN-α administration in the rats 
which could contribute to a different response in compari-
son to monocyte-specific type I IFN elevation in patients 
after MI. Remarkably, following arterial ischaemia, both 
increased type I IFN-related gene expression and type I 
IFN protein levels have been shown to negatively influence 
angio- and arteriogenesis in mice and human [25, 26]. 
Conceivably, timely activation of type I IFN signalling to 
promote tissue repair requires precise modulation through 
different immune cells.
In conclusion, we showed that in patients, monocyte-
specific upregulation of ISGs involved in type I IFN sig-
nalling coincides with beneficial cardiac healing post-MI, 
whereas systemic IFN-α administration in a rat MI model 
detrimentally affected post-MI cardiac healing. These find-
ings underscore the importance of the type I IFN response 
in cardiac healing, although exact regulatory mechanisms 
require further investigations.
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